VIVITRA 440MG ING

About

Trastuzumab is a monoclonal antibody specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein found on the surface of some cancer cells, particularly in certain types of breast and gastric cancers, where its overexpression promotes aggressive tumor growth. Trastuzumab works by binding to the extracellular domain of the HER2 receptor, thereby inhibiting cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells.

This targeted therapy is a cornerstone in the treatment of HER2-positive malignancies, significantly improving patient outcomes by slowing disease progression and increasing survival rates. It is typically administered intravenously, often in combination with chemotherapy.

Uses

• HER2-positive early breast cancer
• HER2-positive metastatic breast cancer
• HER2-positive metastatic gastric cancer
• HER2-positive metastatic gastroesophageal junction adenocarcinoma

Directions For Use

Administer intravenously as an infusion, typically over 30-90 minutes, under the supervision of a healthcare professional. Dosage and frequency are determined by body weight and treatment regimen.

Benefits

• Targets HER2-positive cancer cells specifically.
• Significantly improves survival rates.
• Reduces risk of cancer recurrence.
• Effective in both early and metastatic disease.
• Can be combined with chemotherapy.
• Established standard of care for HER2+ cancers.

Side Effects

• Cardiotoxicity (heart failure, decreased ejection fraction)
• Infusion-related reactions (fever, chills, nausea)
• Diarrhea
• Fatigue
• Headache
• Rash
• Neutropenia
• Anemia
• Peripheral neuropathy
• Nail disorders
• Musculoskeletal pain
• Pulmonary toxicity (rare)

Safety Measures

• Alcohol - No direct interaction with alcohol, but alcohol consumption should be discussed with a doctor, especially during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm, including oligohydramnios and fetal lung hypoplasia.
• Breastfeeding - Not recommended during breastfeeding due to potential for serious adverse effects in the infant.
• Liver - No specific dose adjustment is typically required for liver impairment. Monitor liver function as part of general cancer care.
• Kidney - No specific dose adjustment is typically required for kidney impairment. Monitor kidney function as part of general cancer care.
• Lung - Use with caution in patients with pre-existing lung conditions due to rare risk of pulmonary toxicity, including interstitial pneumonitis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.